Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors
Lund, Sweden — 11 November 2021 — Camurus (NASDAQ STO: CAMX) today announces that dosing has been initiated in the company’s randomized, active-controlled Phase 3 study, SORENTO, which aims to evaluate the efficacy and safety of octreotide subcutaneous depot (CAM2029) in the treatment of patients with neuroendocrine tumors localized in the gastrointestinal tract or pancreas (GEP-NET). “There is a high unmet medical need for new treatment alternatives for patients with neuroendocrine tumors. I am excited about the SORENTO trial, which primarily aims to demonstrate an increased progression-